{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-24-000188","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.011462+00:00","generated_at":"2026-05-30T09:29:49.718732+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Pfizer Q3 revenue $17.7B (+32% YoY); raises FY 2024 guidance on revenue and EPS","bullets":["Q3 2024 revenues of $17.7B, operational growth +32% YoY; ex-Paxlovid/Comirnaty revenue up 14% operationally.","Reported diluted EPS $0.78 vs. ($0.42) in Q3 2023; adjusted diluted EPS $1.06 vs. ($0.17).","Raised FY 2024 revenue guidance to $61-64B (from $59.5-62.5B) and adjusted EPS to $2.75-2.95 (from $2.45-2.65).","Paxlovid revenue $2.7B (+$2.5B YoY); Comirnaty revenue $1.4B (+9% operational).","Cost reduction program on track for at least $5.5B net savings; $4B expected by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-24-000188","json":"https://secwatch.observer/filing/0000078003-24-000188.json","markdown":"https://secwatch.observer/filing/0000078003-24-000188.md","text":"https://secwatch.observer/filing/0000078003-24-000188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000188/0000078003-24-000188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000188/pfe-20241029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:29:49.718732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}